Novo Nordisk sues Hims & Hers over alleged unsafe Wegovy and Ozempic knock‑offs

Cereno Scientific is broadening the development focus of its HDAC inhibitor CS014 to pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Bavarian Nordic has announced an agreement with Eurofarma, granting them exclusive rights to sell and distribute Bavarian Nordic’s chikungunya vaccine, CHIKV VLP, in Brazil.

AstraZeneca has entered a new strategic collaboration agreement with CSPC Pharmaceuticals to advance the development of multiple next-generation therapies for obesity and type 2 diabetes across eight programmes.

BioArctic’s partner Eisai has announced that the supplemental Biologics License Application (sBLA) for Leqembi Iqlik subcutaneous autoinjector (SC-AI) as a weekly starting dose has been granted Priority Review by the US Food and Drug Administration (FDA).

Diamyd Medical is taking the next step in a long-term manufacturing collaboration with APL and, in parallel, is initiating a strategic collaboration with NorthX Biologics to further develop and scale the manufacturing of retogatein (rhGAD65) ahead of commercialization.

The two companies are entering a new phase of their partnership to develop advanced cellular medicines for diabetes.

The company has entered into an exclusive global licensing and research collaboration with a multinational consumer health company to expand the SiPore technology platform into consumer oral health through a partner-led approach.